CLINICAL TRIALS PROFILE FOR PONATINIB HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for ponatinib hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00660920 ↗ | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | Completed | Ariad Pharmaceuticals | Phase 1 | 2008-06-01 | The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies. |
NCT01207440 ↗ | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) | Completed | Ariad Pharmaceuticals | Phase 2 | 2010-09-30 | The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation. |
NCT01424982 ↗ | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Recruiting | Ariad Pharmaceuticals | Phase 2 | 2011-10-05 | This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia. |
NCT01424982 ↗ | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Recruiting | M.D. Anderson Cancer Center | Phase 2 | 2011-10-05 | This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib hydrochloride may be an effective treatment for acute lymphoblastic leukemia. |
NCT01549548 ↗ | Compassionate Use Ponatinib | No longer available | Ariad Pharmaceuticals | 1969-12-31 | The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment. | |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ponatinib hydrochloride
Condition Name
Condition MeSH
Condition MeSH for ponatinib hydrochloride | |
Intervention | Trials |
Leukemia | 45 |
Leukemia, Myeloid | 32 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 29 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 28 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for ponatinib hydrochloride
Trials by Country
Clinical Trial Progress for ponatinib hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for ponatinib hydrochloride
Sponsor Name